Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, a novel antiviral agent that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 that is in Phase I/IIa clinical trial for the treatment of chronic hepatitis C; and AT-889, an investigational, second-generation nucleoside pyrimidine prodrug and other compounds for the treatment of respiratory syncytial virus. It has a Roche License Agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. for development and commercialization related to AT-527 outside of the United States. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.
IPO Year: 2020
Exchange: NASDAQ
Website: ateapharma.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/13/2024 | $2.00 → $6.88 | Underweight → Equal-Weight | Morgan Stanley |
8/10/2023 | Neutral → Underweight | JP Morgan | |
3/2/2022 | $10.00 → $8.00 | Neutral | JP Morgan |
3/1/2022 | $10.00 → $9.00 | Market Perform | SVB Leerink |
2/16/2022 | $11.00 → $10.00 | Market Perform | SVB Leerink |
1/6/2022 | $14.00 → $7.00 | Equal-Weight → Underweight | Morgan Stanley |
11/18/2021 | Outperform → Mkt Perform | SVB Leerink | |
11/18/2021 | $11.00 | Outperform → Market Perform | SVB Leerink |
10/20/2021 | $60.00 → $20.00 | Outperform | SVB Leerink |
10/20/2021 | $61.00 → $16.00 | Overweight → Neutral | JP Morgan |
4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
10-Q - Atea Pharmaceuticals, Inc. (0001593899) (Filer)
8-K - Atea Pharmaceuticals, Inc. (0001593899) (Filer)
8-K - Atea Pharmaceuticals, Inc. (0001593899) (Filer)
144 - Atea Pharmaceuticals, Inc. (0001593899) (Subject)
DEFA14A - Atea Pharmaceuticals, Inc. (0001593899) (Filer)
10-Q - Atea Pharmaceuticals, Inc. (0001593899) (Filer)
8-K - Atea Pharmaceuticals, Inc. (0001593899) (Filer)
DEFA14A - Atea Pharmaceuticals, Inc. (0001593899) (Filer)
DEF 14A - Atea Pharmaceuticals, Inc. (0001593899) (Filer)
8-K - Atea Pharmaceuticals, Inc. (0001593899) (Filer)
BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct acting therapeutics for severe viral diseases, today announced the appointment of Nancy Gail Berry Agrawal, Ph.D., as Executive Vice President of Preclinical Development. Dr. Agrawal previously served as Vice President of Pharmacokinetics, Pharmacodynamics, and Drug Metabolism at Merck & Co., Inc. "We are delighted to welcome Nancy to the Atea team. Her broad scientific and managerial experience in both drug discovery and drug development spanning across multiple therapeutic areas at Merck, will enrich our scientific and c
BOSTON, June 15, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, today announced the appointment of Claudio Avila, MB, BS, Ph.D., as Senior Vice President of Medical Affairs. Dr. Avila previously served as Executive Director, U.S. Medical Strategy and Medical Affairs for COVID-19 at Gilead Sciences. "We are very pleased to welcome Claudio to the Atea team. Claudio's extensive expertise and experience in medical affairs with a focus on COVID-19, hepatitis and HIV as part of his overall interest in serious viral infectious diseases, will complement and s
BOSTON, May 20, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of next-generation therapeutics for severe viral infections, today announced the appointment of Jerome Adams, M.D., M.P.H., to its Board of Directors. Dr. Adams most recently served as Surgeon General of the United States and brings a wide range of experience spanning clinical practice, clinical research, public health, and government agency leadership. "We are honored to welcome Dr. Adams to our Board of Directors, as his unique experience as Surgeon General during the COVID-19 pandemic will undoubtedly help guide Atea as we continue to advance our ant
Morgan Stanley upgraded Atea Pharmaceuticals from Underweight to Equal-Weight and set a new price target of $6.88 from $2.00 previously
JP Morgan downgraded Atea Pharmaceuticals from Neutral to Underweight
JP Morgan reiterated coverage of Atea Pharmaceuticals with a rating of Neutral and set a new price target of $8.00 from $10.00 previously
SVB Leerink reiterated coverage of Atea Pharmaceuticals with a rating of Market Perform and set a new price target of $9.00 from $10.00 previously
SVB Leerink reiterated coverage of Atea Pharmaceuticals with a rating of Market Perform and set a new price target of $10.00 from $11.00 previously
Morgan Stanley downgraded Atea Pharmaceuticals from Equal-Weight to Underweight and set a new price target of $7.00 from $14.00 previously
SVB Leerink downgraded Atea Pharmaceuticals from Outperform to Mkt Perform
SVB Leerink downgraded Atea Pharmaceuticals from Outperform to Market Perform and set a new price target of $11.00
SVB Leerink reiterated coverage of Atea Pharmaceuticals with a rating of Outperform and set a new price target of $20.00 from $60.00 previously
JP Morgan downgraded Atea Pharmaceuticals from Overweight to Neutral and set a new price target of $16.00 from $61.00 previously
BOSTON, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 7, 2024, at 4:30 p.m. ET to report financial results for the third quarter ended September 30, 2024, and to provide a business update. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals website at ir
BOSTON, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced three upcoming poster presentations supporting the combination of bemnifosbuvir and ruzasvir as a potential treatment for Hepatitis C Virus (HCV). The combination of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, is in Phase 2 development for HCV. These data will be presented at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting 2024, being held from November 15-19, 2
BOSTON, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the outcome of the global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir, an oral nucleotide polymerase inhibitor, versus placebo for the treatment of COVID-19. The trial did not meet the primary endpoint of a statistically significant reduction in all-cause hospitalization or death through Day 29 in the monotherapy cohort of 2,221 high-risk patients with mild to moderate COVID-19. In SUNRISE-3, bemnifosbuvir was generally safe and well to
BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that data highlighting the metabolic activation pathway of bemnifosbuvir were published in the peer-reviewed journal, PLOS Biology, in an article titled, "The activation cascade of the broad-spectrum antiviral bemnifosbuvir characterized at atomic resolution." Bemnifosbuvir, an oral nucleotide RNA-dependent RNA polymerase (RdRp) inhibitor, is in Phase 3 development for the treatment of COVID-19 and in Phase 2 development in combination with r
Full Enrollment Achieved in Global Phase 2 Hepatitis C Virus (HCV) Study; Complete SVR12 Results Expected 4Q'24 Bemnifosbuvir and Ruzasvir HCV Data Presented at EASL: Support Best-in-Class Potential with High Antiviral Potency, Low Risk of Drug Interaction, Short Treatment Duration and High Barrier to Resistance Results from COVID-19 Global Phase 3 SUNRISE-3 Trial Expected 2H'24 Conference Call at 4:30 pm ET Today BOSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial resul
BOSTON, July 31, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Wednesday, August 7, 2024, at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2024, and to provide a business update. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals website at ir.atea
97% SVR12 Rate Observed with 8 Weeks of Treatment in Lead-In Cohort of HCV-Infected Patients in Ongoing Phase 2 Clinical Study EASL Presentations Continue to Support Best-in-Class Potential with High Antiviral Potency, Short Treatment Duration, Low Risk of Drug Interaction and High Barrier to Resistance BOSTON, June 05, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced new data from the lead-in cohort (n=60) of the Company's ongoing Phase 2 combination study of bemnifosbuvir, an oral nucleotide NS5B p
BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will present a business update at the Jefferies Healthcare Conference on Wednesday, June 5, 2024 at 10:30 a.m. ET in New York. A live webcast of the presentation will be available here and on the Company's website at https://ir.ateapharma.com/. An archived webcast will be available on Atea's website for at least 90 days following the event. About Atea Atea is a c
Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also Highlight the High Prevalence of Pre-Existing NS5A Resistance-Associated Substitutions (RAS) Detected in HCV-infected Patients BOSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the Company will present new efficacy results, including SVR12 data (primary endpoint), from the Phase 2 lead-in cohort evaluating the combination of bemnifosbuvir (an oral nu
Full Enrollment Achieved in Global Phase 3 SUNRISE-3 Trial for Treatment of COVID-19 with Results Expected 2H'24 Global Phase 2 HCV Study On Track to Report Complete SVR12 Results 2H'24 Multiple Presentations Showcasing Preclinical and New Phase 2 Efficacy Data to be Presented at European Association for the Study of the Liver (EASL) Congress 2024 Conference Call at 4:30 pm ET Today BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the first quarter ended Mar
SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)
SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)
SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)
SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)
SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)
SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)
SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)
SC 13G - Atea Pharmaceuticals, Inc. (0001593899) (Subject)
SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)
SC 13D/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)
BOSTON, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Thursday, November 7, 2024, at 4:30 p.m. ET to report financial results for the third quarter ended September 30, 2024, and to provide a business update. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals website at ir
Full Enrollment Achieved in Global Phase 2 Hepatitis C Virus (HCV) Study; Complete SVR12 Results Expected 4Q'24 Bemnifosbuvir and Ruzasvir HCV Data Presented at EASL: Support Best-in-Class Potential with High Antiviral Potency, Low Risk of Drug Interaction, Short Treatment Duration and High Barrier to Resistance Results from COVID-19 Global Phase 3 SUNRISE-3 Trial Expected 2H'24 Conference Call at 4:30 pm ET Today BOSTON, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial resul
BOSTON, July 31, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Wednesday, August 7, 2024, at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2024, and to provide a business update. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals website at ir.atea
Full Enrollment Achieved in Global Phase 3 SUNRISE-3 Trial for Treatment of COVID-19 with Results Expected 2H'24 Global Phase 2 HCV Study On Track to Report Complete SVR12 Results 2H'24 Multiple Presentations Showcasing Preclinical and New Phase 2 Efficacy Data to be Presented at European Association for the Study of the Liver (EASL) Congress 2024 Conference Call at 4:30 pm ET Today BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the first quarter ended Mar
BOSTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Tuesday, May 14, 2024, at 4:30 p.m. ET to report financial results for the first quarter ended March 31, 2024, and to provide a business update. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals website at ir.at
Final Results Confirm 98% Sustained Virologic Response Rate at Week 4 Post-Treatment (SVR4) from Lead-in Cohort in Phase 2 HCV Study Enrollment in Phase 3 SUNRISE-3 Study Has Surpassed 1,400 COVID-19 Patients in Monotherapy Population; Two Interim Analyses by Independent Data Safety Monitoring Board (DSMB) Planned for 1H'24 with Topline Results Expected 2H'24 Conference Call at 4:30 pm ET Today BOSTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the fourth quar
BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Wednesday, February 28, 2024, at 4:30 p.m. ET to report financial results for the fourth quarter and full year ended December 31, 2023, and to provide a business update. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceutica
Patient enrollment continues in global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for COVID-19; first interim analysis expected 1Q24 Phase 2 bemnifosbuvir and ruzasvir combination trial for hepatitis C (HCV) advances, initial results from 60-patient lead-in cohort expected 1Q24 Conference call at 4:30 pm ET today BOSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea" or the "Company"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the third quarter ended September 30, 2023 and provided a business update. "Promisi
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Wednesday, November 8, 2023, at 4:30 p.m. ET to report financial results for the third quarter ended September 30, 2023, and to provide a business update. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals website at i
Enrollment continues in global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19Phase 3 SUNRISE-3 trial protocol amended to broaden eligibility criteria for high-risk patients and adapt to current COVID-19 environmentEnrollment continues in Phase 2 trial evaluating combination of bemnifosbuvir and ruzasvir for treatment of hepatitis C (HCV) with initial results expected in 4Q23Conference call at 4:30 pm ET today BOSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported finan
Atea Pharmaceuticals Inc (NASDAQ:AVIR) announced Wednesday new data from the lead-in cohort (n=60) of the company’s ongoing Phase 2 combination study of bemnifosbuvir for hepatitis C virus (HCV). With an eight-week treatment duration in 60 patients, the Phase 2 data from the lead-in cohort of non-cirrhotic patients showed a 97% sustained virologic response rate at 12 weeks post-treatment (SVR12), the study’s primary efficacy endpoint. The company will also present preclinical data further demonstrating a high barrier to resistance and pharmacokinetics for bemnifosbuvir and a low risk of drug-drug interactions for ruzasvir. The combination was generally safe and well tolerated. There
97% SVR12 Rate Observed with 8 Weeks of Treatment in Lead-In Cohort of HCV-Infected Patients in Ongoing Phase 2 Clinical Study EASL Presentations Continue to Support Best-in-Class Potential with High Antiviral Potency, Short Treatment Duration, Low Risk of Drug Interaction and High Barrier to Resistance
Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.61) by 22.95 percent. This is a 74.42 percent decrease over losses of $(0.43) per share from the same period last year.
Atea Pharmaceuticals (NASDAQ:AVIR) reported its Q4 earnings results on Wednesday, February 28, 2024 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Atea Pharmaceuticals beat estimated earnings by 6.0%, reporting an EPS of $-0.47 versus an estimate of $-0.5. Revenue was down $0 from the same period last year. Past Earnings Performance Last quarter the company beat on EPS by $0.08 which was followed by a 9.0% drop in the share price the next day. To track all earnings releases for Atea Pharmaceuticals visit their earnings calendar here. This article was generated by Benzinga's automated content engine and reviewed by an editor.
Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.47) per share which beat the analyst consensus estimate of $(0.51) by 7.84 percent. This is a 14.63 percent decrease over losses of $(0.41) per share from the same period last year.
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion. • Golden Ocean Group (NASDAQ:GOGL) is likely to report quarterly earnings at $0.27 per share on revenue of $193.12 million. • Wallbox (NYSE:WBX) is likely to report earnings for its fourth quarter. • Immunocore Hldgs (NASDAQ:IMCR) is estimated to report quarterly loss at $0.28 per share on revenue of $67.23 million. • Royal Bank of Canada (NYSE:RY) is likely to report quarterly earnings at $2.08 per share on revenue of $9.95 billion. • TG Therapeutics (NASDAQ:TGTX) is likely to report quarterly loss at $0.10 per share on revenue of $40.06 mil
Atea Pharmaceuticals (NASDAQ:AVIR) is set to give its latest quarterly earnings report on Wednesday, 2024-02-28. Here's what investors need to know before the announcement. Analysts estimate that Atea Pharmaceuticals will report an earnings per share (EPS) of $-0.50. Atea Pharmaceuticals bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Past Earnings Performance Last quarter the company beat EPS by $0.08, which was followed by a 9
Atea Pharmaceuticals Inc (NASDAQ:AVIR) reported initial data from the first 52 patients in the lead-in cohort of its Phase 2 combination eight-week study of bemnifosbuvir and ruzasvir (RZR) for hepatitis C virus (HCV). What Happened: The company says that the initial data from the Phase 2 combination eight-week study showed a 98% sustained virologic response at week four (SVR4), exceeding the company's efficacy criterion of >90% for continuing the study. Additionally, very rapid kinetics were observed in all 60 patients across genotypes with viral load near or below the lower limit of quantification (LLOQ) at four weeks of treatment, which is supportive of an eight-week treatment regimen